RxDoctor Payments Data

Christopher Regala, MD

Otolaryngology · Aiea, HINPI 1205852217

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 51.9% of the total.

$1,877in general payments, 2019–2025

Across 70 payments — averaging $26.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$975
  • GSK$268
  • Sanofi$217
  • Medtronic$115
  • Intersect ENT, Inc.$88
  • Sanofi-aventis U.S. LLC$53
  • plus $162 from 4 others

What the payments were for

  • Food & beverage$1,82497%
  • Education$533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,877 in reported general payments places this provider in the 60th percentile of 33 otolaryngology providers in Hawaii.

See all otolaryngology providers in Hawaii

Medicare billing

Part B allowed, 2024
$109,342
Medicare patients
372
Services billed
1,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mometasone Furoate48$9,526
Fluticasone Propionate282$4,281
Flunisolide74$3,731
Famotidine121$3,114
Azelastine Hcl32$1,372
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort30$1,348
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth13$1,274
Ipratropium Bromide34$1,001
Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid14$917
Ofloxacin18$785
Omeprazole50$685
Fluocinolone Acetonide Oil11$446
Montelukast Sodium19$362
Albuterol Sulfate HfaAlbuterol Sulfate18$314
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$229

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →